FinscoFinsco

ImmunityBio (US.IBRX)

Capital Allocation Audit · Period: 2019 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.IBRX · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion102.4%→
ROE-→
Cash Conversion-→
D/E Ratio-→
Gross Margin99.5%→
US.IBRX (ImmunityBio) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion   102.4%    →
ROE                   -    →
Cash Conversion       -    →
D/E Ratio             -    →
Gross Margin      99.5%    →
Key Metrics
US.IBRX (ImmunityBio) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 102.4% →
ROE - →
Cash Conversion - →
D/E Ratio - →
Gross Margin 99.5% →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies